Table 1 Baseline characteristics of the study population
Variables | No. of patients | % (or SD) |
|---|---|---|
Total | 73,995 | 100 |
Demographics | ||
Age, mean, SD | 64 | 14.32 |
Age, n, % | ||
< 45 | 7,264 | 9.8 |
45–64 | 28,685 | 38.8 |
65–74 | 18,915 | 25.6 |
> 75 | 19,131 | 25.9 |
Male, n, % | 37,685 | 50.9 |
Calendar year, n, % | ||
2004 | 8,454 | 11.4 |
2005 | 9,000 | 12.2 |
2006 | 8,659 | 11.7 |
2007 | 9,077 | 12.3 |
2008 | 9,463 | 12.8 |
2009 | 9,543 | 12.9 |
2010 | 10,040 | 13.6 |
2011 | 9,759 | 13.2 |
Comorbidity | ||
Diabetes mellitus, n, % | 44,695 | 60.4 |
Hypertension, n, % | 67,053 | 90.6 |
History of medication use | ||
NSAIDs | 55,119 | 74.5 |
Aminoglycosides | 12,882 | 17.4 |
Contrast media | 0 | 0 |
Dosage of medication use (DDD/day/1,000 persons) | ||
NSAIDs | ||
Within 90 days prior to ESRD | 666.3 | |
91–180 days prior to ESRD | 509.1 | |
181–365 days prior to ESRD | 795.3 | |
Aminoglycoside | ||
Within 90 days prior to ESRD | 68.0 | |
91–180 days prior to ESRD | 20.9 | |
181–365 days prior to ESRD | 22.9 | |
Residence, n, % | ||
North | 30,160 | 40.8 |
Central | 17,960 | 24.3 |
South | 23,776 | 32.1 |
East | 2,099 | 2.8 |